Amplified Sciences has developed a proprietary ultra-sensitive optical reporter platform technology that serves as the foundation for its innovative diagnostic tests. This platform enables the creation of multi-omics diagnostic tests, including the PanCystPro™ test, which is specifically designed to assess biomarker levels and activity in pancreatic cyst fluid. The BioMatra™ platform, which powers Amplified Sciences' assays, integrates advanced spectroscopy hardware, chemometric tools, and machine learning algorithms, allowing for the detection of difficult-to-measure biomarkers such as protease activity and low abundance proteins. This technology facilitates a streamlined workflow, enabling multiple analytes to be processed from a single sample, thereby enhancing the efficiency and accuracy of clinical diagnostics.

The PanCystPro™ test exemplifies the application of this technology in the context of pancreatic cancer, a disease where early detection is crucial for improving survival rates. By utilizing the BioMatra platform, the test provides clinicians with a robust algorithm and a novel protease activity assay to stratify the risk of malignancy in patients with pancreatic cystic lesions. This capability not only aids in identifying benign cysts but also contributes to significant cost savings and peace of mind for patients. Amplified Sciences is committed to expanding the versatility of its technology platform to develop innovative assay panels across various sectors of the in-vitro diagnostic market, including cancer and other challenging diseases.

United States

Imagine a world in which devastating disease such as cancer is detected sooner; thus, providing doctors the ability to treat patients earlier with better outcomes. Amplified Sciences is a startup life science diagnostics company focused on accurately detecting and pre-empting the risks of debilitating diseases. The company leverages IP licensed from Purdue University and has developed a platform that can scale to point of care. The lead assay is an ultra-sensitive molecular sensing technology revolutionizing #pancreaticcancer. Enabling early detection of debilitating diseases across oncology and chronic kidney disease.

Amplified Sciences

Company Details